Sign in
CompletedNo phase

Effect of Different Dosage of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With ESLD

Key facts

Who runs it
General Hospital of Shenyang Military Region
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
22 people enrolled
Started
28 Nov 2023
Ended
30 Dec 2025
Type of study
Interventional, 2 groups
Treatments tested
  • umbilical cord-mesenchymal stem cells
Record updated
3 April 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • 18-80 years old
  • End-stage liver disease
  • Sign informed consent

Who cannot take part

  • Liver transplantation recipients
  • Interferon or glucocorticoid therapy within 1 year
  • Acute myocardial infarction, acute heart failure, type I and type II respiratory failure, pulmonary embolism, acute cerebral infarction, acute cerebral haemorrhage and other serious cardiopulmonary diseases
  • Other diseases that may seriously affect the survival
  • Human immunodeficiency syndrome
  • Treated for mental illness
  • Allergic asthma, allergic urticaria, eczema, or a history of multiple drug and food allergies
  • Tumours of the liver or other organs
  • Participation in other clinical trials within 30 days
  • Pregnant or breastfeeding subjects
  • Other circumstances that are unsuitable for participation in this study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

There is a rise in the prevalence of end-stage liver disease during the last decade. End-stage liver disease has become one of the leading causes of death in Western countries. Liver transplantation is the only curative treatment for patients with end-stage liver disease. However, the shortage of donor, high cost, and postoperative complications limit its wide application in clinical practice. At present, stem cell-based therapy has been developed as an alternative treatment for end-stage liver disease. Stem cells can be differentiated into a variety of cell types, and stem cell transplantation, mainly umbilical cord-mesenchymal stem cells, has attracted more and more attention in the treatment of end-stage liver disease. The investigators therefore conduct a randomised controlled trial to investigate the efficacy and safety of human umbilical cord tissue mesenchymal stem cells for the treatment of end-stage liver disease.

The 2 groups in the trial

  • low-dose stem cell group (1×10^6cells/kg per infusion)Treatment being tested

    Peripheral intravenous infusion of low-dose stem cells

    Treatment: umbilical cord-mesenchymal stem cells

  • medium-high-dose stem cell group (3×10^6cells/kg per infusion)Treatment being tested

    Peripheral intravenous infusion of medium-high-dose stem cells

    Treatment: umbilical cord-mesenchymal stem cells

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Different Dosage of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With End-stage Liver Diseases
Record updated
3 April 2026